Showing results (2221-2230 of 2,541) with videos related to
Sort By:
Pageof 255
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2020
Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVEStephen R D Johnston, Roberto Hegg, Seock-Ah Im, et al.Blood|November 26, 2014
Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphomaMuhammad A Mir, Matthew J Maurer, Steven C Ziesmer, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 5, 2015
α-Imaging Confirmed Efficient Targeting of CD45-Positive Cells After 211At-Radioimmunotherapy for Hematopoietic Cell TransplantationSofia H L Frost, Brian W Miller, Tom A Bäck, et al.Plos One|March 19, 2015
Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft modelsSofia H L Frost, Shani L Frayo, Brian W Miller, et al.Blood Cells, Molecules & Diseases|February 6, 2007
Association of ferroportin Q248H polymorphism with elevated levels of serum ferritin in African Americans in the Hemochromatosis and Iron Overload Screening (HEIRS) StudyCharles A Rivers, James C Barton, Victor R Gordeuk, et al.Cancer Research|July 5, 2005
Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imagingTove Olafsen, Vania E Kenanova, Gobalakrishnan Sundaresan, et al.Blood|August 13, 2010
Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual diseaseSteven I Park, Jaideep Shenoi, John M Pagel, et al.Bioorganic & Medicinal Chemistry Letters|April 15, 2014
Identification and optimization of indolo[2,3-c]quinoline inhibitors of IRAK4L Nathan Tumey, Diane H Boschelli, Niala Bhagirath, et al.American Journal of Hematology|April 4, 2020
A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-hodgkin lymphomaVictor A Chow, Joseph G Rajendran, Darrell R Fisher, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2017
Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVEStephen R D Johnston, Roberto Hegg, Seock-Ah Im, et al.Pageof 255